Recro Pharma to Present Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting
May 15, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., May 15, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
Recro Pharma Reports First Quarter 2017 Financial Results
May 11, 2017 07:00 ET
|
Recro Pharma, Inc.
Reports First Quarter 2017 Revenues of $18.7 Million Recently Announced Successful Top-Line Results from Phase III Safety Study of IV Meloxicam On Track to File NDA with U.S. FDA for IV Meloxicam...
Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam
May 09, 2017 07:00 ET
|
Recro Pharma, Inc.
IV Meloxicam 30mg Continues to Demonstrate Solid Safety and Tolerability Profile Company on Track to File NDA with U.S. FDA in Early Q 3 2017 Recro Completes Largest Phase 3 Double Blind Placebo...
Recro Pharma to Present at the 16th Annual Needham Healthcare Conference
March 29, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., March 29, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
Recro Pharma to Present at the Oppenheimer 27th Annual Healthcare Conference
March 16, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., March 16, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
Recro Pharma Reports Year End 2016 Financial Results
March 06, 2017 16:05 ET
|
Recro Pharma, Inc.
Reports 2016 Revenues of $69.3 Million Exceeding Previously Provided Guidance On Track to File NDA with U.S. FDA for IV Meloxicam in Summer 2017 ...
Recro Pharma Appoints Bryan Reasons to Its Board of Directors
March 06, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., March 06, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and other acute care...
Recro Pharma to Present at Upcoming Investor Conferences
March 02, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., March 02, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care...
Recro Pharma Completes Enrollment in Phase III Safety Study of IV Meloxicam
February 27, 2017 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and other acute care...
Recro Pharma Announces Closing of $40 Million Public Offering of Common Stock
December 16, 2016 09:26 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro” or the “Company”) (Nasdaq:REPH), a revenue-generating, specialty pharmaceutical company primarily focused on developing...